<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583554</url>
  </required_header>
  <id_info>
    <org_study_id>H-41830</org_study_id>
    <nct_id>NCT03583554</nct_id>
  </id_info>
  <brief_title>Electrophysiological Biomarkers of AV-101</brief_title>
  <official_title>Electrophysiological Biomarkers of Kynurenine Pathway Modulator AV-101 in Healthy Volunteers: Treating Suicidal Veterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marijn Lijffijt, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michael E. DeBakey VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>VistaGen Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Suicide is 2-7x higher in Veterans than non-veterans, and may be related to brain kynurenine&#xD;
      pathway (KP) dysregulation and NMDA receptor (NMDAR) hyperactivation. Experimental drug&#xD;
      &quot;AV-101&quot; modulates the brain KP, with possible downstream NMDAR deactivation. The&#xD;
      investigators will examine AV-101 NMDAR modulation by testing dose-response effects on&#xD;
      resting state EEG, Mismatch Negativity, and P50 gating. Twelve healthy Operation Enduring&#xD;
      Freedom (OEF) Operation Iraqi Freedom (OIF) and Operation New Dawn (OND) Veterans will be&#xD;
      administered single dose AV-101 720 mg, 1440 mg, and placebo over 3 weeks in a randomized,&#xD;
      double-blind, cross-over trial. Repeated measures General Linear Models will test&#xD;
      dose-response effects. Suicide prevention is an important Veterans Affair (VA) mission. This&#xD;
      study is a first step to testing anti-suicidal effects of AV-101 in Veterans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Suicide is the 10th leading cause of death in the US, and is 2-7 times higher in&#xD;
      Veterans than age- and sex-matched civilians. Standard psychiatric medications (such as&#xD;
      lithium) are anti-suicidal with prolonged use only, and do not impact acute suicidality. A&#xD;
      priority for suicide prevention is to define novel treatment targets for safe and&#xD;
      rapidly-acting interventions. Recent studies have associated suicide and medically severe&#xD;
      suicide attempt (MSSA) with dysregulation of the brain kynurenine pathway (KP), which could&#xD;
      predispose to excessive NMDAR activation, a molecular target purportedly involved in rapid&#xD;
      improvement of suicidality with agents such as ketamine. AV-101 (4-chlorokynurenine,&#xD;
      4-Cl-KYN) is an oral pro-drug that targets KP dysregulation with downstream NMDAR&#xD;
      deactivation. Phase-1 testing showed that AV-101 is metabolized to 7-Cl-KYN in 1.5 to 2 hours&#xD;
      after intake.&#xD;
&#xD;
      Objective: Before testing possible anti-suicidal properties, biomarkers need to be defined to&#xD;
      show that AV-101 engages the NMDAR. The objective of the current study is to define valid and&#xD;
      sensitive neurophysiological markers with a dose-response relationship with AV-101 as&#xD;
      evidence of NMDAR engagement, as well as study safety and tolerability.&#xD;
&#xD;
      Methods: The investigators will recruit 12 healthy and non-psychiatrically ill OEF/OIF/OND&#xD;
      Veterans (age 25-64) who will receive two single doses of AV-101 (720 mg, 1440 mg) and&#xD;
      placebo in a randomized, double-blind, crossover design with one week wash-out between&#xD;
      conditions. Neurophysiological measures collected at baseline (pre-treatment) and hourly for&#xD;
      5 hours following medication intake are resting state EEG, Mismatch Negativity amplitude, and&#xD;
      P50 sensory gating, measures sensitive to modulation of different NMDAR mechanisms. Repeated&#xD;
      measures General Linear Models will be used to test dose-response relationships.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">October 19, 2019</completion_date>
  <primary_completion_date type="Actual">October 19, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>placebo-controlled, randomized, double-blind, cross-over</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The research pharmacist compiles and has unique access to the randomization key</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Neurophysiological markers of AV-101</measure>
    <time_frame>5 hours</time_frame>
    <description>Define valid and sensitive neurophysiological markers with a dose-response relationship with AV-101 (placebo, 720 mg, 1440 mg) as evidence of glutamate NMDA receptor (NMDAR) engagement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma concentration kynurenine pathway metabolites</measure>
    <time_frame>5 hours</time_frame>
    <description>Assess change in blood plasma concentration of quinolinic acid and kynurenic acid from pre-treatment to 5 hours after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) with the Patient Rated Inventory of Side Effects (PRISE)</measure>
    <time_frame>24 hours</time_frame>
    <description>7 item scale assessing side effects in the following symptom domains: Gastrointestinal, Heart, Skin, Nervous System, Eyes/Ears, Genital/Urinary, Sleep, Sexual Functioning. Each domain has multiple symptoms which can be identified. For each domain, the patient rates whether or not the symptoms are tolerable or distressing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic and diastolic blood pressure</measure>
    <time_frame>5 hours</time_frame>
    <description>in mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mood with the Abbreviated Profile of Moods Scale (A-POMS)</measure>
    <time_frame>5 hours</time_frame>
    <description>40 item scale, each item scored on a scale from 0 (absent) - 4 (extreme). Assessed are score for tension (6 items; score ange 0-24), depression (6 items, range 0-24), fatigue (5 items, range 0-20), vigor (6 items, range 0-24), confusion (5 items, range 0-20), anger (7 items, range 0-28), and esteem-related affect (5 items, range 0-20).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dissociative state with Clinician Administered Dissociative States Scale (CADSS]</measure>
    <time_frame>5 hours</time_frame>
    <description>23 item scale assessing symptoms of dissociation, each item scored on a scale from 0 (absent) - 4 (extreme). Assessed is the total score (range: 0 - 92)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>5 hours</time_frame>
    <description>heart beats per second (based on R-R interval in seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in red blood cell count</measure>
    <time_frame>5 hours</time_frame>
    <description>in 10^6/microL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in white blood cell count</measure>
    <time_frame>5 hours</time_frame>
    <description>in 10^3/cubic mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin and albumin</measure>
    <time_frame>5 hours</time_frame>
    <description>in gram/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Aspartate aminotransferase (AST)</measure>
    <time_frame>5 hours</time_frame>
    <description>in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bilirubin, blood urea nitrogen (BUN), creatine</measure>
    <time_frame>5 hours</time_frame>
    <description>in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in thyroid stimulating hormone (TSH)</measure>
    <time_frame>5 hours</time_frame>
    <description>in microU/mL</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AV-101 720 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One time 720 mg L-4-Chlorokynurenine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AV-101 1440 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One time 1440 mg L-4-Chlorokynurenine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AV-101 720 mg</intervention_name>
    <description>Single dose of 2 360 mg AV-101 oral capsules + 2 placebo oral capsules</description>
    <arm_group_label>AV-101 720 mg</arm_group_label>
    <other_name>L-4-Chlorokynurenine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of 4 placebo oral capsules</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo oral dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AV-101 1440 mg</intervention_name>
    <description>Single dose of 4 360 mg AV-101 oral capsules</description>
    <arm_group_label>AV-101 1440 mg</arm_group_label>
    <other_name>L-4-Chlorokynurenine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age 21-64, inclusive&#xD;
&#xD;
          -  US military Veteran&#xD;
&#xD;
          -  Healthy volunteer.&#xD;
&#xD;
          -  Subject and partner are both using at least 1 medically accepted contraception (double&#xD;
             barrier) at randomization until 1 month after single dose&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  History of any Axis 1 psychiatric condition&#xD;
&#xD;
          -  History of psychosis in first-degree family members&#xD;
&#xD;
          -  History of use of psychoactive medication&#xD;
&#xD;
          -  Current use of any medication or vitamins except the pill (women)&#xD;
&#xD;
          -  History of use of any substances of abuse, except for alcohol, caffeine, and nicotine&#xD;
&#xD;
          -  Positive at tests for alcohol and illicit substance at screening and study visits.&#xD;
&#xD;
          -  History of epilepsy, head injury, stroke, primary neurological disorder&#xD;
&#xD;
          -  Clinically significant abnormal laboratory values, vital signs or ECG placing&#xD;
             participants at risk for serious adverse events as determined by the study physician&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Serious, unstable illness including hepatic, renal, gastroenterologic, respiratory,&#xD;
             cardiovascular (including ischemic heart disease), endocrinologic, neurologic,&#xD;
             immunologic, or hematologic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marijn Lijffijt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine and the Michael E. DeBakey VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michael E. DeBakey VA Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Marijn Lijffijt, PhD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Suicide</keyword>
  <keyword>Kynurenine</keyword>
  <keyword>metabolic pathway</keyword>
  <keyword>Veterans</keyword>
  <keyword>OEF/OIF/OND</keyword>
  <keyword>electrophysiology</keyword>
  <keyword>NMDA receptor</keyword>
  <keyword>suicidal ideation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This study is in collaboration with industry partner Vistagen Therapeutics, which provides study medication. Protected health information (PHI) and protected personal information (PII) will not be shared with Vistagen. Study outcomes will be shared as publications.</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>October 13, 2020</submitted>
    <returned>November 3, 2020</returned>
    <submitted>January 13, 2021</submitted>
    <returned>February 5, 2021</returned>
    <submitted>March 16, 2021</submitted>
    <returned>April 8, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

